Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Paediatric oral biopharmaceutics: key considerations and current challenges.

Batchelor HK, Fotaki N, Klein S.

Adv Drug Deliv Rev. 2014 Jun;73:102-26. doi: 10.1016/j.addr.2013.10.006. Review.

PMID:
24189013
2.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J.

Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Review.

PMID:
24060672
3.

Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.

Lennernäs H, Aarons L, Augustijns P, Beato S, Bolger M, Box K, Brewster M, Butler J, Dressman J, Holm R, Julia Frank K, Kendall R, Langguth P, Sydor J, Lindahl A, McAllister M, Muenster U, Müllertz A, Ojala K, Pepin X, Reppas C, Rostami-Hodjegan A, Verwei M, Weitschies W, Wilson C, Karlsson C, Abrahamsson B.

Eur J Pharm Sci. 2014 Jun 16;57:292-9. doi: 10.1016/j.ejps.2013.10.012. Review.

PMID:
24189462
4.

Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.

Batchelor HK, Kendall R, Desset-Brethes S, Alex R, Ernest TB; European Paediatric Formulation Initiative..

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):833-42. doi: 10.1016/j.ejpb.2013.04.015. Review.

PMID:
23665448
5.

In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.

Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C.

Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019.

PMID:
23727464
6.

In vitro models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, Dickinson PA, Dressman J, Holm R, Klein S, Mann J, McAllister M, Minekus M, Muenster U, Müllertz A, Verwei M, Vertzoni M, Weitschies W, Augustijns P.

Eur J Pharm Sci. 2014 Jun 16;57:342-66. doi: 10.1016/j.ejps.2013.08.024. Review.

PMID:
23988843
7.

Paediatric biopharmaceutics classification system: current status and future decisions.

Batchelor H; European Paediatric Formulation Initiative (EUPFI)..

Int J Pharm. 2014 Aug 5;469(2):251-3. doi: 10.1016/j.ijpharm.2014.02.046.

PMID:
24602991
8.

Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.

Bergström CA, Holm R, Jørgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnes J, Taylor R, Mullertz A.

Eur J Pharm Sci. 2014 Jun 16;57:173-99. doi: 10.1016/j.ejps.2013.10.015. Review.

PMID:
24215735
9.

The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.

Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL.

Eur J Pharm Sci. 2014 Jun 16;57:152-63. doi: 10.1016/j.ejps.2014.01.009.

10.

Regional intestinal drug permeation: biopharmaceutics and drug development.

Lennernäs H.

Eur J Pharm Sci. 2014 Jun 16;57:333-41. doi: 10.1016/j.ejps.2013.08.025. Review.

PMID:
23988845
11.

Drug dissolution: significance of physicochemical properties and physiological conditions.

Jambhekar SS, Breen PJ.

Drug Discov Today. 2013 Dec;18(23-24):1173-84. doi: 10.1016/j.drudis.2013.08.013. Review.

PMID:
24042023
12.

A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.

Darwich AS, Pade D, Ammori BJ, Jamei M, Ashcroft DM, Rostami-Hodjegan A.

J Pharm Pharmacol. 2012 Jul;64(7):1008-24. doi: 10.1111/j.2042-7158.2012.01538.x.

PMID:
22686346
13.

Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.

Lennernäs H.

Mol Pharm. 2014 Jan 6;11(1):12-23. doi: 10.1021/mp4003392. Review.

PMID:
24206063
14.

Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT; Members of the BCS Task Force..

Clin Ther. 2012 Nov;34(11):S11-24. doi: 10.1016/j.clinthera.2012.09.014. Review.

15.

Is the full potential of the biopharmaceutics classification system reached?

Bergström CA, Andersson SB, Fagerberg JH, Ragnarsson G, Lindahl A.

Eur J Pharm Sci. 2014 Jun 16;57:224-31. doi: 10.1016/j.ejps.2013.09.010.

PMID:
24075971
17.

Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.

Otsuka K, Shono Y, Dressman J.

J Pharm Pharmacol. 2013 Jul;65(7):937-52. doi: 10.1111/jphp.12059. Review.

PMID:
23738721
18.

Oral biopharmaceutics-current status and identified gaps of understanding.

Lennernäs H, Abrahamsson P, Langguth B.

Eur J Pharm Sci. 2014 Jun 16;57:98. doi: 10.1016/j.ejps.2014.02.001. No abstract available.

PMID:
24508580
19.

The developability classification system: application of biopharmaceutics concepts to formulation development.

Butler JM, Dressman JB.

J Pharm Sci. 2010 Dec;99(12):4940-54. doi: 10.1002/jps.22217.

PMID:
20821390
20.

Identification of biowaivers among Class II drugs: theoretical justification and practical examples.

Rinaki E, Dokoumetzidis A, Valsami G, Macheras P.

Pharm Res. 2004 Sep;21(9):1567-72.

PMID:
15497681
Items per page

Supplemental Content

Support Center